NasdaqCM - Nasdaq Real Time Price • USD
Regulus Therapeutics Inc. (RGLS)
As of 3:53 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 3 |
| Avg. Estimate | -0.22 | -0.11 | -0.51 | -0.61 |
| Low Estimate | -0.44 | -0.13 | -0.57 | -0.75 |
| High Estimate | -0.11 | -0.1 | -0.42 | -0.47 |
| Year Ago EPS | -0.42 | -0.37 | -1.58 | -0.51 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 4 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.44 | -0.41 | -0.4 | -0.39 |
| EPS Actual | -0.42 | -0.37 | -0.4 | -0.4 |
| Difference | 0.02 | 0.04 | 0 | -0.01 |
| Surprise % | 4.50% | 9.80% | 0.00% | -2.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.22 | -0.11 | -0.51 | -0.61 |
| 7 Days Ago | -0.22 | -0.11 | -0.51 | -0.61 |
| 30 Days Ago | -0.21 | -0.11 | -0.52 | -0.96 |
| 60 Days Ago | -0.39 | -0.43 | -1.59 | -1.19 |
| 90 Days Ago | -0.39 | -0.43 | -1.59 | -1.19 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | RGLS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 47.60% | -- | -- | 1.60% |
| Next Qtr. | 70.30% | -- | -- | 10.50% |
| Current Year | 67.70% | -- | -- | 5.20% |
| Next Year | -19.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 39.60% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/25/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 3/19/2024 |
| Initiated | Leerink Partners: Outperform | 3/18/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/18/2024 |
| Maintains | Wells Fargo: Equal-Weight to Equal-Weight | 3/13/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 9/21/2023 |
Related Tickers
LIXT Lixte Biotechnology Holdings, Inc.
3.3524
-1.69%
PEPG PepGen Inc.
10.40
-12.24%
CERO CERo Therapeutics Holdings, Inc.
1.4900
-3.25%
CLRB Cellectar Biosciences, Inc.
3.0650
+0.82%
ELEV Elevation Oncology, Inc.
3.8301
-4.49%
IMRN Immuron Limited
2.2700
-7.35%
XLO Xilio Therapeutics, Inc.
1.1700
-8.59%
NKGN NKGen Biotech, Inc.
1.1000
+27.91%
EQ Equillium, Inc.
1.6100
-6.94%
TRVI Trevi Therapeutics, Inc.
2.7300
+1.69%